No Data
No Data
Susmed: Extraordinary Report
Susmed: Financial Report - Term 9 (2023/07/01 - 2024/06/30)
Susmed: Confirmation letter
Sasumedo Research Memo (7): Decreased revenue and increased losses for the fiscal year ending June 2024.
■Performance trends of Susmed <4263>1. Overview of the performance for the fiscal year ending June 2024 (non-consolidated)The performance for the fiscal year ending June 2024 (non-consolidated) was as follows: Operating revenue decreased by 35.4% compared to the previous year to 3.42 billion yen, operating loss was 364 million yen (compared to a loss of 48 million yen in the fiscal year ending June 2023), ordinary loss was 357 million yen (compared to a loss of 44 million yen), and net loss for the period was 357 million yen (compared to a loss of 50 million yen). The DTx platform business achieved stable revenue, but there was a temporary contract shortfall in the DTx product business.
Sasmethed Research Memo (6): The estimated size of the domestic market for insomnia treatment apps is 350 billion yen.
■ Overview of Sasmido <4263> Business. 5. Domestic Market Size The domestic market size of the development pipeline being pursued by the company (insurance redemption points × target population) is estimated to be 100 billion yen for the insomnia treatment app "Sasmido Med CBT-i (R)" for the target market, and 350 billion yen including potential patients, according to the company's materials. Among these, with regard to the SAM (Serviceable Available Market) which is the targeting demand
SASMED Research Memo (5): Application for partial change approval for manufacturing and sales approval of insomnia treatment app
■ Business Overview of Sasmeldo <4263> 3. For the insomnia treatment app, the partial amendment approval application for manufacturing and sales approval was made in August 2024. Regarding the insomnia treatment app "Sasmeldo Med CBT-i (R)", a sales partnership contract was signed with Shionogi & Co., Ltd. (Granting exclusive sales rights in Japan to Shionogi & Co., Ltd., and receiving a total of up to 4,700 million yen as upfront payment and milestone income based on development progress, etc.) in December 2021, and on February 15, 2023.
No Data
No Data